About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Overall Survival Doesn't Improve On Use Of Long-term Hormonal Therapy in Intermediate-risk PCa Patients

by Rukmani Krishna on October 2, 2013 at 11:36 PM
Font : A-A+

 Overall Survival Doesn't Improve On Use Of Long-term Hormonal Therapy in Intermediate-risk PCa Patients

Results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy were examined by a secondary analysis of the historic RTOG 9202 prostate cancer trial. It concluded that there were no additional benefits when compared to short-term hormonal therapy. The research was presented at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

Men with advanced prostate cancer typically receive hormonal therapy to reduce the level of androgens, or male hormones, in their bodies. Although hormone therapy alone will not cure prostate cancer, lowering androgen levels can reduce prostate tumors size or stall their growth.

Advertisement

The original RTOG 9202 trial (Hanks 2003) evaluated the potential benefits of long-term adjuvant androgen deprivation (LTAD) for two years after initial androgen deprivation, when compared to short-term (initial) androgen therapy (STAD) in mostly high-risk prostate cancer patients receiving external beam radiation therapy (EBRT). Because some intermediate-risk prostate cancer patients were included in the study, a current analysis was conducted to determine if patients in the intermediate-risk subset experienced an additional survival benefit with LTAD.

Researchers reviewed all patients enrolled in RTOG 9202 categorized with intermediate-risk prostate cancer with T2 disease (tumor confined to the prostate), a Prostate Specific Antigen (PSA) of < 10 and a Gleason Score of 7; or, who were immediate-risk prostate cancer patients with T2 disease, PSA of 10-20 and a Gleason Score < 7. A total of 133 patients were analyzed. The LTAD group consisted of 59 patients, and the STAD group consisted of 74 patients. Statistical analysis was used to determine Overall Survival (OS), Disease Specific Survival (DSS) and PSA Failure rates (PSAF), and the median follow-up was more than 11 years. There was no statistical difference in OS with 10-year estimates of 61 percent for the STAD group and 65 percent for the LTAD group. DSS was found to be 96 percent in both groups. PSAF occurred in 38 patients in the STAD group and in 33 in the LTAD group. Ten-year PSAF rates were 53 percent for the STAD group and 55 percent for the LTAD group (p=.99).
Advertisement

"Most clinicians have felt that 'more was better' when it came to blocking testosterone in prostate cancer patients, however, results for the specific endpoints we focused on, OS and DSS, indicate that this was clearly not the case," said Amin Mirhadi, MD, lead author of the study and a radiation oncologist at Cedars-Sinai Medical Center in Los Angeles. "This data supports administering less treatment, which will result in fewer side effects and reduce patients' overall health care costs."

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Black Water: Benefits and Uses
World Hypertension Day 2022 - Measure Blood Pressure Accurately, Control It, Live Longer!
Drinking This Popular Beverage May Drop Dementia Risk
View all
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Reiki and Pranic Healing 

Most Popular on Medindia

Drug Interaction Checker Pregnancy Confirmation Calculator Iron Intake Calculator Drug - Food Interactions Find a Hospital Daily Calorie Requirements Calculate Ideal Weight for Infants Find a Doctor Blood Pressure Calculator Post-Nasal Drip

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2022

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use